- Home
- KOD vs EROK Comparison
KOD vs EROK Comparison
Compare KOD & EROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KOD | EROK |
|---|---|---|
| Founded | 2009 | N/A |
| Country | United States | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.6B |
| IPO Year | 2018 | 2026 |
Fundamental Metrics
Financial Performance| Metric | KOD | EROK |
|---|---|---|
| Price | $41.34 | $22.25 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $35.43 | N/A |
| AVG Volume (30 Days) | ★ 787.2K | 206.4K |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.21 | $20.06 |
| 52 Week High | $47.84 | $22.71 |
Technical Indicators
Market Signals| Indicator | KOD | EROK |
|---|---|---|
| Relative Strength Index (RSI) | 55.56 | 59.89 |
| Support Level | $39.37 | $20.12 |
| Resistance Level | $46.72 | N/A |
| Average True Range (ATR) | 2.96 | 1.05 |
| MACD | -0.04 | 0.12 |
| Stochastic Oscillator | 60.79 | 86.00 |
Price Performance
Historical ComparisonAbout KOD Kodiak Sciences Inc
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.